Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |
---|---|
First Received Date † | February 9, 2001 |
Last Updated Date | June 23, 2005 |
Start Date † | February 2001 |
Current Primary Outcome Measures † | |
Original Primary Outcome Measures † | |
Change History | Complete list of historical versions of study NCT00011089 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures † | |
Original Secondary Outcome Measures † | |
Descriptive Information | |
Brief Title † | Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations |
Official Title † | US Expanded Access Program of Tenofovir Disoproxil Fumarate in the Treatment of HIV-1 Infected Patients Who Have Limited Treatment Options |
Brief Summary | The purpose of this study is to make tenofovir disoproxil fumarate (DF) available to HIV-infected patients who have failed other anti-HIV drug combinations, who have few treatment choices available, and whose disease may get worse. This study will allow patients to obtain tenofovir DF before it is approved for marketing. |
Detailed Description | Patients receive daily doses of tenofovir DF. |
Study Phase | |
Study Type † | Interventional |
Study Design † | Treatment |
Condition † | HIV Infections |
Intervention † | Drug: Tenofovir disoproxil fumarate |
Study Arms / Comparison Groups | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|
Recruitment Information | |
Recruitment Status † | Active, not recruiting |
Enrollment † | |
Completion Date | |
Primary Completion Date | |
Eligibility Criteria † | Inclusion Criteria Patients may be eligible for this study if they:
Exclusion Criteria Patients will not be eligible for this study if they:
|
Gender | Both |
Ages | 18 Years and older |
Accepts Healthy Volunteers | No |
Contacts †† | |
Location Countries † | United States |
Expanded Access Status | |
Administrative Information | |
NCT ID † | NCT00011089 |
Responsible Party | |
Secondary IDs †† | GS-00-955 |
Study Sponsor † | Gilead Sciences |
Collaborators †† | |
Investigators † | |
Information Provided By | NIH AIDS Clinical Trials Information Service |
Verification Date | November 2001 |
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |